#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	14806	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2070	709.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1428	1428	C	841	C,A	793,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26846	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3713	721.2	0	.	n	.	0	T695C	SNP	695	695	T	1043	1043	C	761	C,T	706,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26846	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3713	721.2	0	.	n	.	0	G1337A	SNP	1337	1337	G	1685	1685	A	940	A	891	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26846	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3713	721.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2319	2319	C	849	C,G	813,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26846	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3713	721.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2393	2393	A	865	A	813	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26846	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3713	721.2	1	SNP	n	C2597T	0	.	.	2597	2597	C	2945	2945	C	860	C,T	814,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2090	folP	852	852	100.0	folP.l6.c30.ctg.1	1560	133.6	1	SNP	p	R228S	1	.	.	682	684	AGC	1039	1041	AGC	205;202;202	A;G;C	196;193;190	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5136	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3339	153.1	1	SNP	p	S91F	0	.	.	271	273	TCC	536	538	TCC	153;152;153	T;C;C,A	144;143;141,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5136	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3339	153.1	1	SNP	p	D95G	0	.	.	283	285	GAC	548	550	GAC	150;149;151	G,T;A;C	141,1;141;144	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5136	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3339	153.1	1	SNP	p	D95N	0	.	.	283	285	GAC	548	550	GAC	150;149;151	G,T;A;C	141,1;141;144	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	1694	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1390	121.3	0	.	p	.	0	A39T	NONSYN	115	117	GCC	496	498	ACC	191;192;187	A;C;C	167;173;167	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	1694	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1390	121.3	0	.	p	.	0	R44H	NONSYN	130	132	CGC	511	513	CAC	178;181;182	C;A;C	164;167;171	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	1694	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1390	121.3	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	694	696	CAC	228;228;226	C;A;C	212;208;212	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	1694	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1390	121.3	1	SNP	p	G45D	0	.	.	133	135	GGC	514	516	GGC	183;184;181	G;G;C	169;170;168	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	988	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c17.ctg.1	990	99.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5286	parC	2304	2304	100.0	parC.l15.c17.ctg.1	2817	186.8	1	SNP	p	D86N	0	.	.	256	258	GAC	511	513	GAC	197;195;194	G;A;C	187;185;185	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5286	parC	2304	2304	100.0	parC.l15.c17.ctg.1	2817	186.8	1	SNP	p	S87R	0	.	.	259	261	AGT	514	516	AGT	192;189;189	A;G;T,A	183;180;177,1	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5286	parC	2304	2304	100.0	parC.l15.c17.ctg.1	2817	186.8	1	SNP	p	S87I	0	.	.	259	261	AGT	514	516	AGT	192;189;189	A;G;T,A	183;180;177,1	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5286	parC	2304	2304	100.0	parC.l15.c17.ctg.1	2817	186.8	1	SNP	p	S87W	0	.	.	259	261	AGT	514	516	AGT	192;189;189	A;G;T,A	183;180;177,1	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5286	parC	2304	2304	100.0	parC.l15.c17.ctg.1	2817	186.8	1	SNP	p	S88P	0	.	.	262	264	TCC	517	519	TCC	188;188;188	T;C;C	178;179;179	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4372	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2616	166.3	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1552	1554	GGC	224;224;224	G;G;C	214;212;205	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	3866	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2388	161.1	1	SNP	p	A311V	0	.	.	931	933	GCA	1280	1282	GCA	221;222;221	G;C,T;A	204;204,1;208	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3866	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2388	161.1	1	SNP	p	I312M	0	.	.	934	936	ATC	1283	1285	ATC	220;219;226	A;T;C	207;205;208	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3866	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2388	161.1	1	SNP	p	V316T	0	.	.	946	948	GTG	1295	1297	GTG	222;220;218	G;T;G,A	203;199;198,1	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3866	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2388	161.1	1	SNP	p	V316P	0	.	.	946	948	GTG	1295	1297	GTG	222;220;218	G;T;G,A	203;199;198,1	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3866	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2388	161.1	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1799	1801	ACC	202;203;203	A;C;C	184;189;191	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3866	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2388	161.1	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1853	1855	GCG	197;195;196	G;C;G	175;158;167	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3866	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2388	161.1	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1853	1855	GCG	197;195;196	G;C;G	175;158;167	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3866	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2388	161.1	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1976	1978	GGC	159;161;165	G;G;C	151;146;151	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3866	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2388	161.1	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1985	1987	GGC	161;163;162	G;G,A;C,G	141;142,1;142,1	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3866	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2388	161.1	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2003	2005	CCG	127;127;129	C,G;C;GCCC,GGGCCCC	95,1;97;92,1	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5908	ponA	2397	2397	99.96	ponA.l6.c4.ctg.1	3147	187.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2348	porA	1146	1146	99.83	porA.l6.c4.ctg.1	1769	132.0	0	.	p	.	0	M83fs	FSHIFT	247	247	A	587	587	C	166	C	155	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2882	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1512	189.4	0	.	p	.	0	E48G	NONSYN	142	144	GAA	456	458	GGA	236;236;242	G;G;A	226;221;227	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2882	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1512	189.4	0	.	p	.	0	G50N	NONSYN	148	150	GGC	462	464	AAC	243;243;242	A;A;C,T	223;226;222,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2882	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1512	189.4	0	.	p	.	0	F135L	NONSYN	403	405	TTT	717	719	CTT	211;210;210	C;T;T	200;197;199	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2882	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1512	189.4	0	.	p	.	0	R143G	NONSYN	427	429	AGA	741	743	GGA	199;200;201	G,T;G;A	188,1;191;193	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2882	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1512	189.4	0	.	p	.	0	D171G	NONSYN	511	513	GAT	825	827	GGT	208;211;212	G;G;T	196;201;197	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2882	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1512	189.4	0	.	p	.	0	G189S	NONSYN	565	567	GGC	879	881	AGC	213;214;216	A;G;C	200;203;203	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2882	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1512	189.4	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	945	945	T	213	T	208	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2882	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1512	189.4	1	SNP	p	G120K	0	.	.	358	360	GGT	672	674	GGT	223;223;223	G;G;T	209;211;207	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2882	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1512	189.4	1	SNP	p	A121N	0	.	.	361	363	GCC	675	677	GCC	223;223;225	G;C;C	208;212;214	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2882	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1512	189.4	1	SNP	p	A121D	0	.	.	361	363	GCC	675	677	GCC	223;223;225	G;C;C	208;212;214	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	10548	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4998	210.6	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2059	2061	AAT	257;258;257	A;A;T,A	242;242;242,1	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1120	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	1098	101.4	1	SNP	p	V57M	1	.	.	169	171	ATG	608	610	ATG	218;217;215	A;T;G	205;204;200	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
